Safety and Immunogenicity of BPL-1357, A BPL-Inactivated, Whole-Virus, Universal Influenza Vaccine
NCT05027932
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
45
Enrollment
NIH
Sponsor class
Conditions
Influenza
Interventions
OTHER:
IN Placebo
OTHER:
IM Placebo
DRUG:
BPL-1357
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)